Experienced deal-maker Henrik Stenqvist (pictured above) will take over from retiring Mats-Olof Wallin to become the chief financial officer (CFO) of rare diseases specialist Swedish Orphan Biovitrum (STO: SOBI), the company has announced.
Mr Stenqvist will join the Stockholm-based firm in late spring, becoming a member of its executive committee.
He is currently CFO of Swedish contract development and manufacturing organization Recipharm (STO: RECI) and in total has some 25 years of experience of finance and management positions in pharma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze